Elia et al. also showed that PRODH1 levels are higher in breast cancer metastases compared to primary breast tumors and that PRODH1 inhibition reduces the number of breast cancer-derived lung metastases without any impact on the primary tumors. This evidence concerns the gene PRODH and breast carcinoma.